Stapokibart
Sponsors
Keymed Biosciences Co.Ltd, Beijing Tongren Hospital, First Affiliated Hospital of Chongqing Medical University, Chengdu Kangnuoxing Biopharma,Inc.
Conditions
Atopic Dermatitis (AD)Biological TherapyBiomarkersCRSWNPChronic Rhinosinusitis With Nasal Polyps (CRSwNP)Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)Primary Cutaneous AmyloidosisPrurigo Nodularis
Phase 3
Study on the Treatment of Prurigo Nodularis With Stapokibart Injection
CompletedNCT06424470
Start: 2024-06-25End: 2026-02-11Updated: 2026-06-02
Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis
Not yet recruitingNCT07678931
Start: 2026-08-01End: 2026-12-01Target: 136Updated: 2026-07-01
Phase 4
Unknown Phase
Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis
Not yet recruitingNCT07143864
Start: 2025-09-15End: 2026-12-31Target: 40Updated: 2025-08-27
A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)
Not yet recruitingNCT07459556
Start: 2026-03-01End: 2028-02-01Target: 400Updated: 2026-03-09
A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Active, not recruitingNCT07483268
Start: 2026-05-29End: 2028-02-01Target: 600Updated: 2026-06-05
A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
RecruitingNCT07544862
Start: 2026-06-02End: 2028-02-01Target: 1000Updated: 2026-06-10
Preoperative Stapokibart for Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps
Not yet recruitingNCT07616609
Start: 2026-06-01End: 2028-12-31Target: 48Updated: 2026-06-01